Hudson, John M.
Bailey, Colleen
Atri, Mostafa
Stanisz, Greg
Milot, Laurent
Williams, Ross
Kiss, Alex
Burns, Peter N.
Bjarnason, Georg A.
Funding for this research was provided by:
Terry Fox Foundation
Article History
Received: 16 June 2017
Revised: 5 November 2017
Accepted: 28 November 2017
First Online: 30 January 2018
Compliance with ethical standards
:
: The scientific guarantor of this publication is Georg Bjarnason.
: The authors of this manuscript declare relationships with the following companies:Georg A. Bjarnason: Pfizer Canada: grant support for this study, CME presentations and travel support to oncology meetings. The remaining authors have no further conflicts to disclose.
: Alex Kiss (author) has significant statistical expertise.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: A subset of the patient cohort included in this article has been reported in the following journal publications. The referenced articles were reports on technical protocol development (3), a new DCE-US parameter development (2) or describing using DCE-US vascular volume changes during and after sunitinib therapy to justify changes in sunitinib scheduling (1):1. Bjarnason G A, Khalil B, Hudson JM, Williams R, Milot LM, Atri M, et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol. Elsevier; 2013;32(4):1–8.2. Hudson JM, Williams R, Karshafian R, Milot L, Atri M, Burns PN, et al. Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer. Invest Radiol [Internet]. 2014;49(2):116–23.3. Williams R, Hudson JJM, Lloyd BBA, Sureshkumar AR, Lueck G, Bjarnason GA, et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology [Internet]. 2011 [cited 2012 Oct 12];260(2):581–90.
: • prospective• diagnostic or prognostic study• performed at one institution